A study conducted by Zakowicz et al. (2023) on schizophrenia-spectrum adolescent inpatients (n = 45) and healthy controls (n = 34) found no differences in S100B levels either in exacerbations of psychotic symptoms or after 6–8 weeks of treatment. The gene discussed is S100B; the disease is schizophrenia.